<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">Convalescent plasma therapy is based on the concept of passive immunity. Individuals who recover from SARS-CoV-2 infection have, in principle, developed neutralizing antibodies against the virus
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup>. Collecting plasma, the liquid component of blood, from someone who has recently recovered from COVID-19 and infusing it into someone with an ongoing infection would confer the plasma recipient with antibodies to combat the virus
 <sup>
  <xref ref-type="bibr" rid="CR3">3</xref>
 </sup>. Of note, this is an immediate transient treatment and does not replace the long-lasting immune memory generated by a vaccine. Indeed, high-affinity IgG antibodies have a half-life of up to three weeks in blood
 <sup>
  <xref ref-type="bibr" rid="CR4">4</xref>
 </sup>. Nevertheless, the hope is that the infusion of convalescent plasma enriched in antibodies will substantially boost the recipientâ€™s immediate immune response to clear the virus.
</p>
